Sort
10,766 grants matching “checkpoint inhibitor”
Strategies for Cancer Immunotherapy Clinical Trials
$1,151,937Jeffrey Schlom · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA
Human Immune Responses to Tumor Antigens for Cancer Immunotherapy
$1,151,937Jeffrey Schlom · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA
Preclinical Mouse Models for Studying Immune Checkpoint Inhibitor Response
$1,151,331Glenn T. Merlino · Division Of Basic Sciences - Nci · ZIA · FY2020 · CA
Genetically Engineered Mouse Models to Study Melanoma Genesis and Progression
$1,151,331Glenn T. Merlino · Division Of Basic Sciences - Nci · ZIA · FY2020 · CA
Preclinical drug development in pancreatic cancer
$1,150,996Udo Rudloff · Division Of Basic Sciences - Nci · ZIA · FY2014 · CA
Studies of Human T Regulatory Cells
$1,148,221Ethan Shevach · National Institute Of Allergy And Infectious Diseases · ZIA · FY2025 · AI
COBRE Phase III
$1,147,500Marjan Boerma · Univ Of Arkansas For Med Scis · P30 · FY2025 · GM
Rapid highly multi-plexed immuno-profiling of solid tumors by SpectralEdge imaging
$1,145,798Eric Kaldjian · Rarecyte, Inc. · R44 · FY2020 · CA
Development of Tumor and Immuno-Metabolism Based Small Molecule Therapeutics for Refractory Breast Cancer
$1,145,470Vincent Sandanayaka · Nirogyone Therapeutics, Llc · R44 · FY2020 · CA
Systematic Identification and Pharmacological Targeting of Tumor Dependencies for Precision Cancer Medicine
$1,144,955Andrea Califano · Columbia University Health Sciences · U01 · FY2019 · CA
Preclinical drug development in pancreatic cancer
$1,140,440Udo Rudloff · Division Of Basic Sciences - Nci · ZIA · FY2017 · CA
Epigenetic and immunologic aspects of neuroendocrine cancers
$1,140,320Nitin Roper · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA
Strategies for improving early detection, diagnosis and treatment of liver cancer
$1,137,130Xin Wei Wang · Division Of Basic Sciences - Nci · ZIA · FY2025 · CA
Symptomatic Toxicities & Quality of Life among Diverse Individuals Receiving Immune Checkpoint Inhibitors for Metastatic Cancer.
$1,131,820Patricia Ingrid Moreno · University Of Miami School Of Medicine · R37 · FY2025 · CA
Targeting the fibroblast-immune cell crosstalk to relieve immune suppression in the pancreatic cancer microenvironment
$1,128,458Marina Pasca Di Magliano · University Of Michigan At Ann Arbor · R01 · FY2025 · CA
A Phase 1 Clinical Trial Evaluating the Novel Small Molecule Immuno-Oncology Antagonist SX-682 Alone and With Pembrolizumab in Metastatic Melanoma
$1,125,311Stuart J Kahn · Syntrix Biosystems, Inc. · R44 · FY2018 · CA
Molecular Regulation of B cells and T cells in Human SLE
$1,124,031Ignacio E. Sanz · Emory University · U19 · FY2020 · AI
Collaborative Project
$1,124,031Jeremy M. Boss · Emory University · U19 · FY2020 · AI
Proteogenomic studies to understand mechanisms and drivers of resistance to immunotherapies
$1,122,409Amanda G Paulovich · Fred Hutchinson Cancer Center · U01 · FY2024 · CA
The Boston Lung Cancer Survival Cohort
$1,113,227David C Christiani · Harvard University D/B/A Harvard School Of Public Health · U01 · FY2024 · CA
Initiation of DNA Replication in Mammalian Cells
$1,112,639Mirit Aladjem · Division Of Basic Sciences - Nci · ZIA · FY2011 · CA
The Houston Center for Acquired Resistance Research (H-CARR)
$1,112,099Jeffrey Nicholas Myers · University Of Tx Md Anderson Can Ctr · U54 · FY2024 · CA
Initiation of DNA Replication in Mammalian Cells
$1,110,045Mirit Aladjem · Division Of Basic Sciences - Nci · ZIA · FY2010 · CA
Human Immune Responses to Tumor Antigens for Cancer Immunotherapy
$1,107,978Jeffrey Schlom · Division Of Basic Sciences - Nci · ZIA · FY2017 · CA
Human Immune Responses to Tumor Antigens for Cancer Immunotherapy
$1,107,849Jeffrey Schlom · Division Of Basic Sciences - Nci · ZIA · FY2018 · CA